Ten fellows will join the National Academies’ new Biotechnology Regulatory Fellowship Program, launched recently to engage early-career professionals in developing the evidence basis needed to meet future regulatory challenges presented by novel products of biotechnology. These fellows will identify possible regulatory frameworks for the cutting-edge products expected to emerge over the next several decades and provide government agencies with options for effective regulation.

On November 15, 2020, after 4 months in large-scale Phase 3 clinical testing, Moderna received resounding proof that its new class of medicines based on messenger RNA encased in lipid nanoparticles could be safely deployed as a highly effective vaccine to combat the COVID-19 pandemic.